Background: A polymorphism consisting of a C825T substitution in the G-protein beta(3) subunit gene (GNB3) has been associated with enhanced human atrial inward rectifier potassium currents regarding the TT genotype. Therefore, we investigated a possible impact of the GNB3 C825T polymorphism on atrial fibrillation in an association study.
Methods: Two hundred ninety-one consecutive patients admitted to our center with atrial fibrillation (age, 58 +/- 10 years) and 292 consecutive control patients without atrial tachyarrhythmias (59 +/- 11 years) were genotyped for the C825T polymorphism. Patients with coronary heart disease, valvular heart disease, or cardiomyopathy were excluded from the study. Both patient groups had a similar incidence of cardiovascular risk factors (hypertension, hypercholesterolemia, body mass index).
Results: The prevalence of the GNB3 TT genotype was significantly lower in patients with atrial fibrillation (5.8%) than in the control group (12.0%); however, no significant differences in the frequencies of the CT and CC genotypes were found. The TT genotype was associated with a 54% decrease in the adjusted risk (OR from a multivariant model, 0.46; 95% CI, 0.24 to 0.87; P =.02) for the occurrence of atrial fibrillation.
Conclusions: The current study suggests an association between the GNB3 TT genotype and a reduced risk for the occurrence of atrial fibrillation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ahj.2004.03.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis.
BMC Cardiovasc Disord
January 2025
The second Affiliated Hospital of Xi'an Jiaotong University, Xinjiang Hospital (People's Hospital of Xinjiang Uygur Autonomous Region, Bainiaohu Hospital), Urumqi, Xinjiang, 830026, People's Republic of China.
Background: Several studies showed higher risks of cardiovascular complications to have been observed in patients with type 2 diabetes mellitus (T2DM). Atrial fibrillation (AF) and atrial flutter have been more pronounced in patients with hyperglycemia. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are now considered as second-line treatment for patients with T2DM following inadequate glycemic control with first line agents.
View Article and Find Full Text PDFEfficacy and safety of atrial fibrillation ablation in patients with aged 80 years or older. Letter to the editor (response to Kataoka N, et al.).
Heart Vessels
January 2025
Department of Cardiovascular Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan.
Transcardiac gradients of pro-cholecystokinin, cholecystokinin, and gastrin in patients with and without heart failure with reduced ejection fraction.
Peptides
January 2025
Department of Cardiology, Rigshospitalet, Copenhagen, Denmark, Department of Clinical Medicine, University of Copenhagen, Denmark.
Background: Cholecystokinin (CCK) is secreted from the intestines in response to food intake. We previously reported that the CCK gene is also expressed in the mammalian heart, and it has been hypothesized that proCCK could be a novel cardiac biomarker. However, it is not known whether cardiac gene expression leads to secretion in humans.
View Article and Find Full Text PDFNet Benefit of Early Anticoagulation for Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Importance: The net clinical effect of early vs later direct oral anticoagulant (DOAC) initiation after atrial fibrillation-associated ischemic stroke is unclear.
Objective: To investigate whether early DOAC treatment is associated with a net clinical benefit (NCB).
Design, Setting, And Participants: This was a post hoc analysis of the Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation (ELAN) open-label randomized clinical trial conducted across 103 sites in 15 countries in Europe, the Middle East, and Asia between November 6, 2017, and September 12, 2022, with a 90-day follow-up.
Left atrial appendage velocity, association with inflammatory indices in non-valvular atrial fibrillation patients.
Future Cardiol
January 2025
Echocardiography research Center, Rajaie cardiovascular medical and research Center, Iran University of Medical Science, Tehran, Iran.
Introduction: Decreased left atrial appendage emptying velocity (LAAV) is a marker for thrombus formation. This study evaluates the association between LAAV and inflammatory indices in non-valvular atrial fibrillation (AF) patients.
Methods: The study population was 1428 patients with AF, 875 of whom enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!